

Best Polyclonal Antibody Manufacturers 2023

SICGEN Antibodies is a developer, manufacturer, and marketer of polyclonal antibodies used for cell biology research. The company was founded back in 2008 as a spin-off from the University of Coimbra by José Ramalho, a Portuguese scientist whose previous credits include work at the NOVA University of Lisbon. Based in a small village in the Coimbra district, the business has the Production Unit, which is comprised of a lab space and an animal house which produces hundreds of goat antibodies per year. We speak with José to find out more about this interesting work done in the heart of Portugal.

SICGEN Antibodies (SICGEN) develops, produces, and markets these innovative antibodies, which have demonstrably been used successfully in a variety of life science research areas. For instance, antibodies against fluorescent proteins, such as GFP, mCherry, and tdTomato, have featured prominently in such research publication as Nature, Cell, and Science. As of 2023, SICGEN offers a product line that consists of over 300 products, with these antibodies mostly being used for research purposes in the areas of Western Blotting (WB), Immunofluorescence (IF), and Immunocytochemistry (IHC).


While many are already utilised for ELISA, immunoprecipitation, and other such biochemical techniques, SICGEN continuously strives to develop new antibody related products that continue to benefit research and the wider industry. SICGEN also currently produces custom polyclonal antibodies for leading national and international institutions, including universities, research institutions, pharmaceutical manufacturers, and biotechnology distributors worldwide, but particularly specialising in the North American, European, and Far East markets.

The success of the institution is ultimately a result of the focusing of research on niche areas where clear gaps exist in the supply of high-quality antibodies. As a spin-off from an academic institution with scientist founders, it was easy for the team to identify and focus on the production of the sort of antibodies that were in high demand, and an ability to successfully anticipate the evolution of some key scientific areas of study resulted in a competitive advantage, and cutting-edge technologies which focus on increasing or improving antibody production are always embraced by the company.

It is this commitment to innovation that José believes will drive SICGEN to eventually becoming a global leader in the production of polyclonal antibodies and related products, offering the highest calibre of service and competitive prices for its clients. Research and development in the antibody industry plays a pivotal role in further advancing scientific research through the providing of tools that enable the study of processes and molecules.

Antibodies are widely used in the fields of cell biology, biochemistry, and immunology, with the industry bearing witness to considerable growth over the past few years. To manage demand, SICGEN continues to evolve, improving the quality, specificity, and reproducibility of the antibodies, and through collaboration with researchers, industry professionals, and regulatory bodies, the team can ensure the continued advancement in this field can meet the needs of the scientific community and better lives.

Since its establishment, SICGEN, like other organisations in the antibody industry, has faced difficult challenges and undergone significant changes. Chief among these is antibody cost, which can be especially expensive for those developed with specific targets and applications in mind. Guaranteeing the reproducibility and specificity of the antibodies has also served as a major challenge, and this has resulted in the implementation of guidelines and standards, prompting an emphasis on antibody validation.



To manage costs, SICGEN always explores in-depth strategies to reduce production costs without compromising on quality, which led to its implementation of attaining goat antibodies to streamline manufacturing processes and improve scalability. The team also ensures rigorous antibody validation protocols are upheld through the transparent recording of validation data. Through its prioritising of specificity and reproducibility, SICGEN has built trust with researchers and successfully differentiates itself from other competitors in the market, many of whom suffer from stagnation as a result of not being innovative enough.

Looking ahead to the future, SICGEN continues to develop, producing and marketing a range of new antibodies to further fill gaps in the market. In addition, the company will attempt to reach customers in new markets, increasing distributor channels and implementing a sample programme. The continued use of the latest technological developments is also on the agenda, with this providing new opportunities for innovation both now and down the line, helping the company to attain its goal of one day becoming the premier global producer of polyclonal antibodies.

Contact: José Ramalho
Company: SICGEN Antibodies
Web Address: www.sicgen.pt